Our Archives section provides access to previously published issues, ensuring a comprehensive resource for researchers, practitioners, and educators.
Explore Past Issues
- Volume 1(Issue 1) JANUARY- JUNE 2025
Research Articles
Intelligent Clinical Copilot for Comprehensive Medical Risk Assessment
Vol.1(1); Pages:1-8. Published on May-2025
Abstract
Because healthcare is always changing, pharmacy programs now need to develop students who are expert, fast LLMs have recently shown impressive results on mock medical exams, but they struggle when existing models need to make clinical decisions that involve thinking logically about uncertainty. We develop RiskAgent which works alone as an autonomous copilot, addressing medical risk prediction by using more than 387 ready clinical tools. As an alternative to solely fine-tuning or making prompts, RiskAgent uses well-established tools to make sure the outcomes it creates are accurate, clear to interpret and reliable. We build MedRisk, the first benchmark designed for medical risk prediction, by gathering 12,352 cases representing 154 diseases, 86 symptoms, 50 specialties and 24 organ systems. The 8B-parameter version of RiskAgent reaches 76.33% accuracy which is much greater than that of the leading commercial LLMs GPT-4.5 and o1 and more than two times that of GPT4o. Significantly, the model demonstrates strong performance in cases where data is low and the disease specialty is rare or Cancer. Using a modular approach and trusted tools from medicine, RiskAgent ensures its deployment is waste-free, lowers costs and keeps patient privacy in mind. Open-source models from S7 (7B parameters) to S1 (1B parameters) are included in the system, together with code and datasets.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Comparing the 2015 ACPE Accreditation Framework with the 2018 Chinese Clinical Pharmacy Education Standards: An Analysis
Vol.1(1); Pages:9-17. Published on May-2025
Abstract
The study carries out a comprehensive comparison between the 2018 National Accreditation Standard for Teaching Quality of Clinical Pharmacy in China and the 2015 Accreditation Standards and Guidelines of the ACPE in the United States. Because China is quickly developing its healthcare system and now needs reliable, high-quality pharmaceutical training on par with international standards, this comparison has become important. The paper compares the main aspects, structure of the curriculum, governance, support for students, teacher qualifications and evaluation methods of both systems. As seen by the study, although China’s 2018 accreditation standard is a key achievement for developing clinical pharmacy education, significant differences still exist. These challenges consist of low attention to curriculum changes, poorly specified roles for administrators and a shortage of well-defined methods to assess both student progress and the success of programs. Furthermore, language and rules in China serve to lock its education system out of the global and professional world. The final section of the study recommends steps for bringing China’s accreditation up to the global level expected for Pharm.D. programs. Among these, the initiative involves broadening the science curriculum, establishing business and leadership plans, supporting quality in teaching and making closer connections to the outcomes aimed by ACPE.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Improving Healthcare for Rare Genetic Conditions in China: A Critical Call
Vol.1(1); Pages:18-26. Published on May-2025
Abstract
Since rare genetic diseases affect only a few people, together they influence many and create a major health problem in China. Despite being chronic, progressive and potentially fatal, many of these disorders go unidentified and are poorly managed because awareness, infrastructure and genetic help are lacking. In China, the fast development of genomic technologies has not resulted in clinics becoming available to everyone, mainly in underserved rural areas. All healthcare stakeholders, including doctors, labs and genetic counselors, must band together to improve diagnosis, clinician knowledge, newborn screening and genetic counseling. Besides, having a national rare disease registry, investing in translational research and passing laws to support the field can all help patients. The paper argues that China needs to develop a strong, fair and ongoing system for managing rare diseases. It urges policymakers, medical experts, researchers and patient advocate groups to join forces to help people and their families facing rare genetic diseases.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Evolution of Elderly Healthcare and Pharmaceutical Care: A Historical Overview
Vol.1(1); Pages:27-34. Published on May-2025
Abstract
Learning about geriatric medicine and pharmacy reveals important stages in the history of healthcare, showing how the population, science and society have changed. Because populations across the globe are aging, healthcare providers have identified the distinct and challenging health care requirements of older adults. The overview maps the steps that brought geriatric medicine from ancient times and early curing traditions to the medical specialty it is today. It examines how living longer and having more chronic conditions connected to old age prompted the use of specific medical and drug treatments. There is an increasing focus on personalized care for seniors due to the growth of geriatric pharmacotherapy which concerns adjusting drug dosages to older adults’ bodies and limiting excessive use of many medications. Furthermore, the abstract points out the importance of teamwork between geriatricians and pharmacists to help improve the therapy outcomes and the quality of life of elderly people. By examining these developments in relation to the past and current policies, the book highlights why it is vital to keep innovating, consider ethics and base aging care on research. As a result, this perspective prepares us to guide the future integration of geriatric ideas into total and lasting healthcare systems.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Pulmonary Arterial Hypertension Patient Profiles: Findings from a New Real-World Data Registry
Vol.1(1); Pages:35-43. Published on May-2025
Abstract
PAH is a severe disease that slowly causes the vascular system to resist pressure, until the right heart gives out and leads to death. Experts must consider the diversity among patients with PAH to achieve better patient outcomes. We studied real-world patient data from an advanced data bank, giving us a full overview of the population, medical care and treatment approaches in individuals with PAH. Repository access to longitudinal records, lab tests, pictures, heart condition reports and medicines enables doctors to see patient medical journeys, diseases they have and how treatments have worked over time. The results demonstrate that the time when patients develop heart failure, their sex balance, what causes it, what its main features are and what their response is to guidelines all differ widely. Crucially, the research points out that certain people and treatment areas are being overlooked and could gain from extra attention. Using this kind of evidence enhances the way PAH is understood and supports tailoring medicine for those with pulmonary hypertension.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
